Given their role in activating immune responses, PAMPs and their mimics are being investigated as potential cancer therapies. For instance, TLR agonists are being tested as adjuvants in cancer vaccines to enhance their efficacy. Additionally, oncolytic viruses, which can selectively infect and kill cancer cells, often work by releasing PAMPs that activate anti-tumor immune responses.
